Read by QxMD icon Read

Deauville lymphoma

Sameer Bakhshi, Sainath Bhethanabhotla, Rakesh Kumar, Krishankant Agarwal, Punit Sharma, Sanjay Thulkar, Arun Malhotra, Deepa Dhawan, Sreenivas Vishnubhatla
BACKGROUND: Data about significance of (18)F-FDG positron emission tomography (PET) at interim assessment and end of treatment in pediatric Hodgkin lymphoma (HL) are limited. METHODS: Patients (≤18 years) with HL were prospectively evaluated with contrast-enhanced computed tomography (CECT) and PET combined with low-dose CT(PET-CT) at baseline, post 2 cycles of chemotherapy and post completion of treatment. Revised international working group criteria (RIW) and Deauville (DA) five point-scale for response assessment by PET-CT were used...
October 6, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Seung Hwan Moon, Ah Young Lee, Won-Seog Kim, Seok Jin Kim, Young Seok Cho, Yearn Seong Choe, Byung-Tae Kim, Kyung-Han Lee
Subjects were 45 patients with angioimmunoblastic T-cell lymphoma (AITL) who underwent 2-[(18)F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) at baseline and interim after 2-4 cycles. Predictors of progression-free survival (PFS) and overall survival (OS) were assessed. Positive interim PET/CT (Deauville score ≥3) was a significant independent predictor of poor PFS (Hazard ratio, 4.42; p=.028), and showed marginal significance to predict OS (p=.065). Less than 60% decrease in the average change of maximum standardized uptake value normalized by lean body mass (SULmax) also was a significant independent predictor of poor PFS (Hazard ratio, 12...
October 9, 2016: Leukemia & Lymphoma
Anna Kocurek, Bogdan Małkowski, Agnieszka Giza, Wojciech Jurczak
AIM OF THE STUDY: Determining the role of PET/CT imaging in the evaluation of treatment efficacy in primary mediastinal B-cell lymphoma (PMBCL). MATERIAL AND METHODS: Retrospective analysis of seven PMBCL patients, treated at the University Hospital in Krakow, with interim PET/CT after the third course of chemo-immunotherapy.The analysis was based on the calculation of exact tumour volume and metabolic activity, compared with initial values (directly after diagnosis)...
2016: Contemporary Oncology Współczesna Onkologia
Eun Ji Han, Joo Hyun O, Hyukjin Yoon, Seung Eun Jung, Gyeongsin Park, Byung Ock Choi, Seok-Goo Cho
F-18-fluoro-2-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is essential for monitoring response to treatment in patients with diffuse large B-cell lymphoma (DLBCL) and qualitative interpretation is commonly applied in clinical practice. We aimed to evaluate the interobserver agreements of qualitative PET/CT response in patients with DLBCL and the predictive value of PET/CT results for clinical outcome.PET/CT images were obtained for patients with DLBCL 3 times: at baseline, after 3 cycles of first-line chemotherapy (interim), and after completion of chemotherapy...
September 2016: Medicine (Baltimore)
S A Milgrom, W Dong, M Akhtari, G L Smith, C C Pinnix, O R Mawlawi, E M Rohren, N Garg, H H Chuang, Z Abou Yehia, J Reddy, J R Gunther, E M Osborne, Y Oki, M Fanale, B Dabaja
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Luca Ceriani, Sally Barrington, Alberto Biggi, Bogdan Malkowski, Ur Metser, Annibale Versari, Maurizio Martelli, Andrew Davies, Peter W Johnson, Emanuele Zucca, Stéphane Chauvie
The International Extranodal Lymphoma Study Group (IELSG)-37 is a prospective randomized trial assessing the role of consolidation mediastinal radiotherapy after immunochemotherapy to patients with newly diagnosed primary mediastinal large B-cell lymphoma (PMBCL). It is a positron emission tomography (PET) response-guided study where patients obtaining a complete metabolic response on an end-of-therapy PET-computed tomography (CT) scan evaluated by a central review are randomized to receive radiotherapy or no further treatment...
August 22, 2016: Hematological Oncology
Dominick Lamonica, Daniel A Graf, Mihaela C Munteanu, Myron S Czuczman
: In a single-arm, phase 2 clinical trial, bendamustine-rituximab (BR) demonstrated an overall response rate (ORR) of 82% among 45 patients with relapsed/refractory mantle cell lymphoma (MCL), with manageable tolerability. A prespecified (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) analysis was conducted to assess the predictive value of the metabolic response to BR compared with the response by International Working Group (IWG) criteria. METHODS: Adult patients with relapsed/refractory MCL underwent FDG-PET at screening and following 6 cycles of BR therapy...
July 28, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Anita Kumar, Carla Casulo, Joachim Yahalom, Heiko Schöder, Paul M Barr, Philip Caron, April Chiu, Louis S Constine, Pamela Drullinsky, Jonathan W Friedberg, John F Gerecitano, Audrey Hamilton, Paul A Hamlin, Steven M Horwitz, Alexandra G Jacob, Matthew J Matasar, Gianna N McArthur, Susan J McCall, Alison J Moskowitz, Ariela Noy, Maria L Palomba, Carol S Portlock, David J Straus, Nicholas VanderEls, Stephanie L Verwys, Joanna Yang, Anas Younes, Andrew D Zelenetz, Zhigang Zhang, Craig H Moskowitz
This multicenter pilot study assessed the safety and efficacy of brentuximab vedotin (BV) and AVD (adriamycin, vinblastine, and dacarbazine) followed by 30 Gy involved site radiation therapy (ISRT). Patients with newly diagnosed, early stage classical Hodgkin lymphoma (HL) with unfavorable-risk features were treated with 4 cycles of BV and AVD. Patients who achieved a negative positron emission tomography (PET) scan (Deauville score of 1-3) received 30 Gy ISRT. Thirty patients received treatment and were assessable for toxicity...
September 15, 2016: Blood
Lale Kostakoglu, Andre Goy, Giovanni Martinelli, Dolores Caballero, Michael Crump, Gianluca Gaidano, Tara Baetz, Rena Buckstein, Gregg Fine, Guenter Fingerle-Rowson, Claude Berge, Deniz Sahin, Oliver Press, Laurie Sehn
An exploratory analysis of 75 follicular lymphoma patients treated with obinutuzumab or rituximab induction therapy (IT) for 4 weeks in the phase II GAUSS study aimed to determine whether positron emission tomography (PET) results could predict progression-free survival (PFS) and tumor response. The proportion of patients with a PFS event (progression or death) was higher in those who were PET-positive after IT (assessed using Deauville five-point scale criteria; 35/52, 67%) than PET-negative (5/20, 25%); the hazard ratio for progression or death was 0...
June 24, 2016: Leukemia & Lymphoma
Salvatore Annunziata, Annarosa Cuccaro, Maria Lucia Calcagni, Stefan Hohaus, Alessandro Giordano, Vittoria Rufini
OBJECTIVE: To evaluate the prognostic role of the ratio between target lesion and liver SUVmax (rPET) in patients with Hodgkin lymphoma (HL) undergoing interim FDG-PET/CT and to compare rPET with the 5-point Deauville Score (5p-DS). METHODS: Sixty-eight patients with HL undergoing interim FDG-PET/CT after first courses of chemotherapy were evaluated. The receiver operating characteristic (ROC) approach was applied to identify the optimal cutpoint of rPET with respect to progression free survival (PFS)...
October 2016: Annals of Nuclear Medicine
Federico Fallanca, Pierpaolo Alongi, Elena Incerti, Luigi Gianolli, Maria Picchio, Irfan Kayani, Jamshed Bomanji
PURPOSE: To evaluate the accuracy and prognostic value of FDG PET/CT for response assessment after treatment in patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) when using the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC). METHODS: This retrospective study included 101 patients (35 HL, 66 NHL) who underwent early restaging FDG PET/CT after treatment. Scans were evaluated using the IHPC and DC. Two thresholds of positivity for the DC were used: a score of at least 3 (DC3, i...
September 2016: European Journal of Nuclear Medicine and Molecular Imaging
Andrea Riccardo Filippi, Cristina Piva, Mario Levis, Annalisa Chiappella, Daniele Caracciolo, Marilena Bellò, Gianni Bisi, Umberto Vitolo, Umberto Ricardi
PURPOSE: To validate, in a monoinstitutional cohort with extended follow-up, that post-rituximab chemotherapy (R-CT) (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) is a prognostic factor allowing discrimination of primary mediastinal B-cell lymphoma (PMBCL) patients at higher risk for progression after radiation therapy. METHODS AND MATERIALS: We analyzed 51 patients, and (18)FDG-PET scans were re-examined evaluating both the Deauville 5-point scale (D5PS) score and the standardized uptake value (SUV) of residual activity, if present...
July 15, 2016: International Journal of Radiation Oncology, Biology, Physics
Yasmin Reyal, Irfan Kayani, Adrian J C Bloor, Christopher P Fox, Ronjon Chakraverty, Ann-Marie Sjursen, Adele K Fielding, Marcus Ben Taylor, Mark J Bishton, Emma C Morris, Kirsty J Thomson, Nigel Russell, Stephen Mackinnon, Karl S Peggs
Pretransplant (18)F-fluorodeoxyglucose (FDG) positron emission tomography status is an important prognostic factor for outcomes after autologous stem cell transplantation (SCT) in Hodgkin lymphoma (HL), but its impact on outcomes after allogeneic SCT remains unclear. We retrospectively evaluated outcomes after T cell-depleted allogeneic SCT of 116 patients with nonprogressive HL according to pretransplant Deauville scores. Endpoints were overall survival (OS), progression-free survival (PFS), relapse rate (RR), and nonrelapse-related mortality (NRM)...
July 2016: Biology of Blood and Marrow Transplantation
Sally F Barrington, N George Mikhaeel
Positron emission tomography (PET)-CT was recommended in updated international guidelines for staging/restaging of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). In FL, PET was previously regarded as a research application only. This review concentrates on new publications related to PET in these diseases. In DLBCL, PET appears appropriate for staging using prognostic indices established with CT and baseline PET parameters, e.g. metabolic tumour volume, are prognostic of outcome. Early complete metabolic response (CMR) predicts end-of-treatment CMR with excellent prognosis...
June 2016: Current Hematologic Malignancy Reports
L Valls, C Badve, S Avril, K Herrmann, P Faulhaber, J O'Donnell, N Avril
The majority of aggressive lymphomas is characterized by an up regulated glycolytic activity, which enables the visualization by F-18 FDG-PET/CT. One-stop hybrid FDG-PET/CT combines the functional and morphologic information, outperforming both, CT and FDG-PET as separate imaging modalities. This has resulted in several recommendations using FDG-PET/CT for staging, restaging, monitoring during therapy, and assessment of treatment response as well as identification of malignant transformation. FDG-PET/CT may obviate the need for a bone marrow biopsy in patients with Hodgkin's lymphoma and diffuse large B cell lymphoma...
July 2016: Blood Reviews
Oliver W Press, Hongli Li, Heiko Schöder, David J Straus, Craig H Moskowitz, Michael LeBlanc, Lisa M Rimsza, Nancy L Bartlett, Andrew M Evens, Erik S Mittra, Ann S LaCasce, John W Sweetenham, Paul M Barr, Michelle A Fanale, Michael V Knopp, Ariela Noy, Eric D Hsi, James R Cook, Mary Jo Lechowicz, Randy D Gascoyne, John P Leonard, Brad S Kahl, Bruce D Cheson, Richard I Fisher, Jonathan W Friedberg
PURPOSE: Four US National Clinical Trials Network components (Southwest Oncology Group, Cancer and Leukemia Group B/Alliance, Eastern Cooperative Oncology Group, and the AIDS Malignancy Consortium) conducted a phase II Intergroup clinical trial that used early interim fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to determine the utility of response-adapted therapy for stage III to IV classic Hodgkin lymphoma. PATIENTS AND METHODS: The Southwest Oncology Group S0816 (Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma) trial enrolled 358 HIV-negative patients between July 1, 2009, and December 2, 2012...
June 10, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Neta Goldschmidt, Geffen Kleinstern, Marina Orevi, Ora Paltiel, Dina Ben-Yehuda, Alex Gural, Diana Libster, David Lavie, Moshe E Gatt
PURPOSE: Outcomes in primary mediastinal B cell lymphoma (PMBL) improved with the introduction of dose intense treatments, consolidation radiotherapy and rituximab. DA-EPOCH-R, which omits radiotherapy has been adopted with worldwide enthusiasm, despite lack of proven superiority in randomized trials. We aimed to evaluate the course and outcome of PMBL using an alternative intensive rituximab-containing regimen, RCHOP-RICE. We also evaluated the prognostic value of (18)FDG-PET-CT (PET-CT)...
May 2016: Cancer Chemotherapy and Pharmacology
Regine Kluge, Lidia Chavdarova, Martha Hoffmann, Carsten Kobe, Bogdan Malkowski, Françoise Montravers, Lars Kurch, Thomas Georgi, Markus Dietlein, W Hamish Wallace, Jonas Karlen, Ana Fernández-Teijeiro, Michaela Cepelova, Lorrain Wilson, Eva Bergstraesser, Osama Sabri, Christine Mauz-Körholz, Dieter Körholz, Dirk Hasenclever
PURPOSE: The five point Deauville (D) scale is widely used to assess interim PET metabolic response to chemotherapy in Hodgkin lymphoma (HL) patients. An International Validation Study reported good concordance among reviewers in ABVD treated advanced stage HL patients for the binary discrimination between score D1,2,3 and score D4,5. Inter-reader reliability of the whole scale is not well characterised. METHODS: Five international expert readers scored 100 interim PET/CT scans from paediatric HL patients...
2016: PloS One
Ur Metser, Ravi Mohan, Vaughan Beckley, Hadas Moshonov, David Hodgson, Grainne Murphy
PURPOSE: Based on the International Harmonization Project (IHP) criteria, positron emission tomography (PET) response assessment of residual nodal masses in patients with lymphoma after completion of therapy is performed visually using mediastinal blood pool as the reference. The primary objective of this study was to define the optimal reference for PET response assessment. Secondary aim was to assess if morphological criteria on computed tomography (CT) may improve performance of PET...
March 2016: Nuclear Medicine and Molecular Imaging
Yu Kong, Lili Qu, Yuekai Li, Dai Liu, Xuemin Lv, Jiankui Han
We hypothesized that the objective treatment response of patients with diffuse large B-cell lymphoma (DLBCL) was affected by many factors such as pathophysiological, biological, and pharmaceutical mechanisms. This retrospective study aimed to evaluate the predictive significance of clinical prognostic factors and interim fluorine-18-fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT), and to find a new prognostic predictor significantly associated with DLBCL patients' outcome...
February 2016: Medicine (Baltimore)
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"